NUS - NYSE
Nu Skin Enterprises, Inc.
$5.28
-5.7%Nu Skin Enterprises, Inc. develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, and ageLOC LumiSpa skin treatment and cleansing devices; and ageLOC Boost, as well as a range of other cosmetic and personal care products. The company also offers ageLOC Youth nutritional supplements, ageLOC TR90 weight management and body shaping systems, LifePak nutritional supplements, ageLOC Meta nutritional supplements, and Beauty Focus Collagen+ skin care supplements, as well as other weight management products. In addition, it is involved in the research and product development of skin care products and nutritional supplements. Further, the company operates retail stores and service centers in Mainland China. It sells its products under the Nu Skin, Pharmanex, and ageLOC brands. The company promotes and sells its products directly, as well as through distributors and Website. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
At a Glance
Live SnapshotNu Skin Enterprises, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Acceptable margins but limited operational leverage. Operating expense control is important.
Net Profit Margin
Strong net margins indicate efficient operations and favorable tax/interest management.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Nu Skin Enterprises, Inc. Income Statement
NUS • NYSE
| Nu Skin Enterprises, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
1.5B | 1.7B | 2B | 2.2B | 2.7B | 2.6B | 2.4B | 2.7B | 2.3B | 2.2B | 2.2B | 2.6B | 3.2B | 2.2B | 1.7B | 1.5B | 1.3B | 1.2B | 1.2B | 1.1B | |
GROSS PROFIT | ||||||||||||||||||||
(453.8M) | (550.2M) | (611.9M) | (630.9M) | (675.2M) | (658M) | (581.4M) | (634.1M) | (502.1M) | (500.5M) | (489.5M) | (478.4M) | (505.8M) | (353.2M) | (322.6M) | (272.4M) | (243.6M) | (228.6M) | (209.3M) | (195.2M) | |
1B | 1.2B | 1.4B | 1.6B | 2B | 1.9B | 1.8B | 2B | 1.8B | 1.7B | 1.8B | 2.1B | 2.7B | 1.8B | 1.4B | 1.3B | 1.1B | 1B | 948.4M | 920.2M | |
OPERATING INCOME | ||||||||||||||||||||
(940.5M) | (1.3B) | (1.3B) | (1.5B) | (1.8B) | (1.7B) | (1.6B) | (1.7B) | (1.5B) | (1.5B) | (1.5B) | (1.7B) | (2.1B) | (1.5B) | (1.2B) | (1B) | (929M) | (893.6M) | (857.7M) | (854.4M) | |
(940.5M) | (1.1B) | (1.3B) | (1.4B) | (1.7B) | (1.7B) | (1.6B) | (1.7B) | (1.5B) | (1.5B) | (1.5B) | (1.7B) | (2.1B) | (1.5B) | (1.2B) | (1B) | (929M) | (893.6M) | (857.7M) | (833.5M) | |
(0.0) | (13M) | (22.6M) | (0.0) | (27.2M) | (23.3M) | (0.0) | (23M) | (22M) | (24.3M) | (20.1M) | (18.9M) | (18M) | (14.9M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
90.9M | -151.6M | 48.3M | 110.8M | 234M | 257.6M | 267.4M | 240.9M | 274.5M | 231.1M | 244.7M | 352.2M | 554.1M | 340.8M | 233.7M | 217.1M | 147.7M | 125.4M | 70.9M | 54.7M | |
PRE-TAX INCOME | ||||||||||||||||||||
(13.9M) | (26.4M) | (25.6M) | (21.9M) | (11M) | (13.1M) | (19.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (4.8M) | (6.9M) | (7.8M) | (7.8M) | (8.3M) | (0.0) | |
-13.9M | -26.4M | -25.6M | -11.5M | 157K | 24K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.8M | -6.9M | -5.8M | -6.9M | -8.3M | 0.0 | |
(0.0) | (189.4M) | -2.8M | (48.5M) | (24.7M) | -23.3M | (0.0) | -21.2M | -8.9M | -18.3M | -32.7M | -53.7M | (2.8M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (20.8M) | |
105.3M | -23.5M | -21.7M | -21.9M | -1.5M | -1.3M | -12.3M | -21.2M | -8.9M | -18.3M | -32.7M | -53.7M | 2.8M | 4.4M | -7M | -9.4M | -6.6M | -24.8M | -2.4M | -2M | |
196.2M | -175.1M | 26.6M | 89M | 232.5M | 256.2M | 255.2M | 219.7M | 265.6M | 212.8M | 212M | 298.5M | 556.9M | 345.2M | 226.8M | 207.6M | 141.1M | 100.7M | 68.5M | 52.7M | |
NET INCOME | ||||||||||||||||||||
(36M) | -28.5M | (18M) | -15.8M | (85.2M) | (64.9M) | (81.6M) | (97.8M) | (136.1M) | (69.8M) | (78.9M) | (109.3M) | (192.1M) | (123.6M) | (73.4M) | (71.6M) | (51.3M) | (35.3M) | (24.6M) | (19.9M) | |
160.2M | -146.6M | 8.6M | 104.8M | 147.3M | 191.4M | 173.6M | 121.9M | 129.4M | 143.1M | 133M | 189.2M | 364.9M | 221.6M | 153.3M | 136.1M | 89.8M | 65.3M | 43.9M | 32.8M |
SEC Filings
NUS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 08, 2026 | May 06, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 08, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | May 28, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 12, 2026 | February 12, 2026 | 2026 |
Related Guides
Continue your NUS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.